2023 World Conference on Lung Cancer (Posters)-P1.08. Delivery of ATRA and Gefitinib by Polyphenylalanine Nanosystem to Overcome EGFR-TKI Resistance in Lung Adenocarcinoma

P1.08. Delivery of ATRA and Gefitinib by Polyphenylalanine Nanosystem to Overcome EGFR-TKI Resistance in Lung Adenocarcinoma - PDF(Abstract)

Back to course

Pdf Summary

This study focuses on overcoming resistance to EGFR-TKI (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor) in lung adenocarcinoma by delivering a combination of all-trans retinoic acid (ATRA) and gefitinib using a polyphenylalanine nanosystem. EGFR-TKIs are commonly used in non-small cell lung cancer (NSCLC) patients, but resistance to these drugs can lead to tumor progression and metastasis. The researchers developed nanoparticles (Gef/ATRA@8P4-NPs) loaded with gefitinib and ATRA using a nanoprecipitation method. The nanoparticles showed favorable physicochemical properties and were able to be efficiently taken up by gefitinib-resistant lung adenocarcinoma cells. The loaded nanoparticles exhibited a stronger anti-tumor effect and higher apoptotic activity compared to free gefitinib. In animal models, the nanoparticles showed superior therapeutic efficacy and safety, inhibiting tumor growth and metastasis. Western blot analysis indicated that the nanoparticles reversed EGFR-TKI resistance by promoting tumor cell apoptosis and inhibiting differentiation, invasion, and metastasis. Overall, the polyphenylalanine-derived nanoparticles provide a promising strategy for the treatment of advanced metastatic EGFR-TKI-resistant lung adenocarcinoma.

Asset Subtitle

Bin Xu

Meta Tag

Speaker Bin Xu

Topic Tumor Biology: Translational Biology - Drug Resistance

Keywords

EGFR-TKI resistance

lung adenocarcinoma

all-trans retinoic acid

gefitinib

polyphenylalanine nanosystem

nanoparticles

tumor progression

metastasis

therapeutic efficacy

apoptotic activity